← Eichor
Study identifier: NCT05275686 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

Condition: Eustachian Tube Dysfunction  ·  Sponsor: Cedars-Sinai Medical Center

PhasePhase 2
Planned participants80
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersYes

About this study

Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).

This description comes directly from the study's public registry record.

Talk to the study team

Missael Vasquez  ·  424-315-2437  ·  missael.vasquez@cshs.org

Laura Sarmiento, CCRP  ·  3104234295  ·  laura.sarmiento@cshs.org

Always discuss trial participation with your own doctor first.

Locations (4)

Cedars-Sinai Medical CenterLos Angeles, California, United StatesRecruiting
Sacramento Ear, Nose & ThroatSacramento, California, United StatesRecruiting
Indiana UniversityIndianapolis, Indiana, United StatesRecruiting
Ochsner Health SystemNew Orleans, Louisiana, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05275686